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Lack of a role for MRPI in platinum drug resistance in
human ovarian cancer cell lines
SY Sharp, V Smith, S Hobbs and LR Kelland
CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
Summary The level of expression of the multidrug resistance-associated protein (MRP1) in a panel of human ovarian carcinoma cell lines
and their variants with acquired cisplatin resistance was determined using Western blotting. No overexpression of MRP1 was detected in any
of the cell lines. In addition, we have transfected the MRP1 gene into an intrinsically cisplatin-resistant cell line SKOV3, previously shown to
have elevated levels of glutathione (GSH). The MRP1-transfected line SKOV3-S2 was shown to be cross-resistant to doxorubicin, vincristine
and etoposide but not to paclitaxel, vinblastine and platinum agents, such as cisplatin, JM216 [bis-acetato-ammine-dichloro-cyclohexylamine
platinum (IV)] and AMD473 [cis-ammine dichloro (2-methyl-pyridine) platinum (II)]. No cross-resistance to any of the platinum agents was
observed in a MRP1-overexpressing human lung cancer cell line with acquired doxorubicin resistance. Reduction of GSH levels (80-90%) by
buthionine sulphoximine (BSO) produced significant potentiation in cisplatin sensitivity in the parental SKOV3, the vector-alone control
SKOV3-puro and the MRP1 -transfected line SKOV3-S2. The degree of sensitization was similar in all cell lines (1.6-fold). However, selective
sensitization by BSO to vincristine was observed in the MRP1-transfected line (4.1-fold) but not in the vector control. No significant differences
were observed in cisplatin accumulation in the SKOV3-puro and the SKOV3-S2 cells, although both these transfected lines accumulated
significantly more than the parental line. Our results suggest that MRP1 does not play a significant role in platinum resistance in the human
tumour cell lines investigated in this study.
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Multidrug resistance (MDR) has been shown to be caused by
enhanced drug efflux mediated by two members of the ATP-
binding cassette (ABC) family of transporter proteins, the 170-
kDa P-glycoprotein (P-gp) (Juliano and Ling, 1976) and the
190-kDa multidrug resistance-associated protein (MRP1) (Cole et
al, 1992). MRP1 was discovered because ofits overexpression in a
number of MDR human tumour cell lines that do not overexpress
the P-gp.
Several reports have shown that MRP1 can act as a GS-X pump
that is involved in the detoxification of heavy metals (Zaman et al,
1995; Ishikawa et al, 1996). This is mainly achieved by trans-
porting drugs that are conjugated or co-transported with GSH
(Muller et al, 1994; Jedlitschky et al, 1996). One ofthe main mech-
anisms of cisplatin resistance is increased cellular detoxification
via elevated GSH (Andrews and Howell, 1990). Moreover,
Ishikawa et al (1994) have shown overexpression of the GS-X
pump in cisplatin-resistant human promyelocytic leukaemia HL-60
(HL-60/R-CP) cells, in which GSH was elevated. Conversely, other
reports have suggested that MRPI is not the major pump respon-
sible for cisplatin resistance through studies in which the MRP]
gene was transfected into a cervical cell line, HeLa (Cole et al,
1994), and into a non-small-cell lung cancer cell line (SW-1573)
(Zaman et al, 1994), or using a pair of cisplatin-sensitive and
acquired resistant sublines (De Vries et al, 1995).
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Cisplatin is a widely used anti-cancer drug, particularly in the
treatment ofhuman ovarian, testicular, bladder, and head and neck
cancers, but drug resistance is known to limit efficacy (Loehrer
and Einhom, 1984). In view of the above conflicting data, our aim
in this study was to assess the possible role of MRP1 in platinum
resistance primarily in human ovarian carcinoma cell lines, using
established pairs ofcisplatin-sensitive cells and cells with acquired
cisplatin resistance, as well as parental lines of differing intrinsic
sensitivity (>100-fold). Three pairs oflines with acquired cisplatin
resistance have been studied; two in which transport defects have
previously been described, 41M/4lMcisR (Loh et al, 1992) and
A2780/A2780cisR (Holford et al, 1998), one in which elevated
GSH has been shown to contribute to resistance, A2780/
A2780cisR (Kelland et al, 1994) and the other (CHRl/CHlcisR) in
which resistance is attributable to DNA repair (Kelland et al,
1992). In addition, we have transfected a full-length MRP1 cDNA
into an intrinsically cisplatin-resistant human ovarian carcinoma
cell line, SKOV-3, and determined the drug resistance properties
of the transfected line. This cell line was selected as it has been
widely used in our previous studies of platinum drug resistance
(Mistry et al, 1991; McKeage et al, 1994) and was shown to
possess undetectable levels of MRP1 (see below). Our previous
studies have shown that the main biochemical mechanisms of
cisplatin resistance in the SKOV-3 cells are attributable to
increased GSH levels (Mistry et al, 1991) and to the inhibition of
formation ofbifunctional interstrand DNA lesions, possibly by the
formation of GSH adducts (McKeage et al, 1994). We have
included investigation of two analogues of cisplatin of differing
chemical reactivity and lipophilicity, JM216 (Kelland et al, 1993)
and AMD473 (Holford et al, 1998), both recently introduced into
the clinic.
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Further platinum drug cross-resistance studies have been
conducted using a pair of human non-small-cell lung cancer cell
lines with acquired doxorubicin resistance, i.e. CORL23 and
CORL23/R, in which the resistant line has been previously shown
to overexpress MRP (Barrand et al, 1993).
MATERIALS AND METHODS
Cisplatin and JM216 were synthesized by and obtained from the
Johnson Matthey Technology Centre (Reading, Berkshire, UK).
AMD473 was obtained from AnorMED (Langley, British
Columbia, Canada). Chemicals were purchased from Sigma
Chemicals (Poole, Hants, UK), unless otherwise stated.
Cell lines
Five 'parent' human ovarian carcinoma cell lines were used in this
study (SKOV3, 41M, CHI, A2780 and HX/62). Details of their
establishment and biological properties have been described previ-
ously (Hills et al, 1989; Kelland et al, 1993). In addition, variants
with acquired cisplatin resistance have been generated by continu-
ously exposing cells to increasing concentrations of drug (41M/
41McisR, CHI/CH1cisR, A2780/A2780cisR) (Behrens et al,
1987; Kelland et al, 1992). Cytotoxicity determinants for cisplatin
against the panel of cell lines described above have been reported
(Kelland et al, 1993). Briefly, the 96-h IC5, values ([tM) ofcisplatin
[as assessed by the sulphorhodamine B (SRB) assay] were 0.26 for
41M, 1.23 for 41McisR6 [resistance factor (RF) of 4.7], 0.11 for
CHI, 0.71 for CHlcisR (RF of 6.4), 0.3 for A2780, 4.8 for
A2780cisR (RF of 16), 4.4 for SKOV3 and 12.6 for HX/62 cell
lines. The human non-small-cell lung cancer cell lines CORL23
and CORL23/R (doxorubicin resistant) were kindly provided by
Dr P Twentyman (Cambridge, UK).
All cells grew as monolayers in Dulbecco's modified Eagle
medium (DMEM) containing 10% heat inactivated fetal calf
serum (Life Technologies, Scotland, UK), 2 mM L-glutamine.
0.5 tg ml' hydrocortisone and minimal essential medium (MEM)
non-essential amino acids in a 10% carbon dioxide, 90% air
atmosphere, and all cell lines were free of Mycoplasma.
Vector construction and transfection
The bicistronic plasmid vector pIRES-P (code number F250,
EMBL accession number Z75185) was used to express MRPI in
eukaryotic cells. This vector expresses a single bicistronic mRNA
driven from the human cytomegalovirus immediate early
enhancer/promoter and uses the internal ribosome entry site from
encephalomyocarditis virus to direct translation ofthe downstream
pcic gene encoding for puromycin acetyl transferase (de la Luna et
al, 1988). Transfected clones surviving selection with puromycin
are therefore biased towards expression of the upstream gene
(Rees et al, 1996). A cDNA containing the complete coding
sequence for MRP1 (Zaman et al, 1994) was cloned into the
multiple cloning site of F250 as an N/eI-Notl fragment, resulting
in the vector F253 (Figure 1).
The intrinsically cisplatin-resistant cell line SKOV3 was trans-
fected with the F250 vector or the vector containing the MRP1
coding sequence (F253 vector) using the cationic liposome-
mediated transfection (lipofection) method (Boehringer
Mannheim) and was performed according to the manufacturer's
instructions. Briefly, 5 x 105 cells were seeded in each well of a
six-well plate and were exposed to DNA (3 pg) and the transfec-
tion reagent (DOTAP) (8 tl) in serum-free Earle's balanced salt
solution for 6 h. The content of the wells was then replaced with
normal growth medium and incubated for a further 48 h. The cells
were trypsinized and seeded into 24-well plates, and puromycin
was added to the cells at 0.3 Htg ml-' (a concentration previously
determined to kill all non-transfected cells). Stable transfectants
were selected after 3 weeks and analysed by Western blot. For this
study, two transfected clones (SKOV3-S2 and SKOV3-S4) were
used and were grown continuously for up to 6 months in normal
growth medium (+ 10% FCS) in the absence ofpuromycin.
Western blot
Cells (I x 107) were trypsinized, washed with phosphate-buffered
saline (PBS) and suspended in 100 t of lysis buffer [10ml of
150 mm sodium chloride and 50 mm Tris-HCI, pH 7.5, 500 pl of
phenylmethylsulphonyl fluoride (PMSF) (20 mm stock), 2 tl of
Aprotinin (10 mg ml-' stock), 2 ,l ofLeupeptin (10 mg ml-' stock),
100 ,ul of sodium orthovanadate (10 mm stock), 100 .tl ofNP40 and
100gl of20% sodium dodecyl sulphate (SDS)] at 4°C for 1 h. Cells
were then centrifuged at 12 000 r.p.m. (MSE Microcentrifuge) at
4°C for 15 min. The supernatant (total protein extract) was used for
protein determination (Pierce BCA assay, Rockford, IL, USA) and
Western blot analysis (Sharp et al, 1994). The mouse monoclonal
antibody to MRP1 (MRPlm6) was kindly provided by Professor R
Scheper, Amsterdam. The doxorubicin-resistant human large-cell
lung cancer cell line COR-L23/R previously shown to overexpress
MRPI (Barrand et al, 1993) was used as the positive control.
Assessment of cytotoxicity
Cytotoxicity (2 and 96 h) was measured by the SRB assay as
described previously (Loh et al, 1992). The platinum agents,
cisplatin (at 500ltM), JM216 (at 500 ItM) and AMD473 (at I mM)
were dissolved in 0.9% saline. Stock solutions of doxorubicin
(Bristol Myers Squibb Pharmaceuticals), vinblastine (Farmitalia
Carlo Erba, Milton Keynes, UK) and vincristine were made up
to 1 mM and 500 IIM, respectively, in sterile water. Etoposide
(Farmitalia Carlo Erba) was dissolved at 34 mM, and paclitaxel
(Bristol Myers Squibb Pharmaceuticals) was dissolved at 5 mm in
ethanol. All aqueous drug solutions were filter sterilized before use.
The effect of GSH depletion by BSO on the cytotoxicity of
cisplatin (and vincristine) was assessed in all cell lines according
to Mistry et al (1991). Briefly, cells were exposed to 50 ltM BSO
(the highest non-toxic dose) or medium for 24 h. Different concen-
trations ofcytotoxic drug were then added for 2 h, after which the
drug was washed off and cell survival was assessed after 96 h as
described above.
GSH assay
The total GSH content of the cell lines was measured by an
enzymatic assay using glutathione reductase (Mistry et al, 1991).
The GSH content was expressed as nmol GSH per mg of protein.
The effect of BSO on GSH levels was determined by treating cells
(1-4 x 106) with 50 pM BSO for 24 h, followed by GSH extraction.
Intracellular platinum accumulation
The effect of concentration on cisplatin uptake (2 h) in the cell
lines was determined as described previously using flameless
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Figure 1 The puromycin-resistant bicistronic IRES vector containing the
complete coding sequence for MRP1 (F253 vector)
atomic absorption spectrometry (Perkin Elmer 1100B and HGA
700, Beaconsfield, Bucks, UK) (Loh et al, 1992). Cellular plat-
inum levels were expressed as nmol platinum per mg ofprotein.
RESULTS
Western blot
The levels of expression of MRP1 in the panel of human ovarian
cell lines and their variants with acquired cisplatin resistance were
determined by immunoblotting using the MRP1m6 monoclonal
antibody. The previously reported MRP1-positive doxorubicin-
resistant human large-cell lung line (COR-L23/R) was included as
a positive control. Figure 2A shows that there was no detectable
expression ofMRPl in any ofthe cell lines.
MRPl levels in the parental SKOV3, the vector-alone control
SKOV3-puro and two selected MRPI-transfected clones
(SKOV3-S2 and SKOV3-S4) were also determined. No over-
expression of MRP1 was observed in the SKOV3 and SKOV3-
puro lines (Figure 2B). The two MRPl-transfected clones
overexpressed the 190-kDa MRP1, SKOV3-S2 having a higher
expression ofMRP1 than SKOV3-S4. The majority of subsequent
experiments were performed using the SKOV3-S2 clone. There
were no significant differences in doubling times between all
cell lines (SKOV3, 23.1+4.0 h; SKOV3-puro, 19.3±2.3 h; and
SKOV3-S2, 22.7±6.7 h).
Cytotoxicity assessment
Cross-resistance profiles for SKOV3-puro and SKOV3-S2 to
cisplatin, JM216, AMD473, doxorubicin, etoposide, paclitaxel and
vinblastine showed that at 2- and 96-h drug exposure, the SKOV3-
S2 line was cross-resistant to doxorubicin and etoposide only
(Rf >1.5) (Figure 3). A similar cross-resistance profile was
obtained in the SKOV3-S4 line, although the lower level ofMRPI
expression did not correlate with a lower level of cross-resistance
to doxorubicin (RF, 96 h exposure, 2.6) and etoposide (Rf4.4). Rf
values for the other drugs were: cisplatin 1.5, JM216 1.9,
AMD473 1.6, paclitaxel 1.2 and vinblastine 1.3.
Figure 2 (A) Western blot for MRP1 in a panel of human ovarian cell lines.
Lane 1, molecular weight markers; lane 2, COR-L23/R (positive control);
lane 3, 41M; lane 4, 41McisR; lane 5, CH1; lane 6, CH1cisR; lane 7, A2780;
lane 8, A2780cisR; lane 9, HX/62. (B) Western blot for MRP1 in the parental
SKOV3 cells, the vector-alone control SKOV3-puro, and the two MRP1-
transfected clones, SKOV3-S2 and SKOV3-S4
Further cross-resistance studies were conducted using the
CORL23 and CORL23/R (MRPI overexpressing) non-small-cell
lung cancer lines (Table 1). The CORL23/R cell line was 23.5-fold
resistant to doxorubicin and exhibited cross-resistance to etopo-
side and partial cross-resistance to vincristine and paclitaxel.
However, non-cross-resistance, and even a trend of greater sensi-
tivity, was observed to cisplatin, JM216 and AMD473.
Effect of BSO on cisplatin and vincristine sensitivity
To determine the effect of BSO on the GSH levels in SKOV3,
SKOV3-puro and SKOV3-S2 cells, the total amount of GSH was
determined. After 24-h exposure to 50 gM BSO, the levels ofGSH
were decreased by 80-90% in all cell lines (Table 2).
The 2-h cytotoxicity of cisplatin in the absence and presence of
BSO was assessed in these cell lines. With the addition of BSO,
there was a significant potentiation ofcisplatin sensitivity in all cell
lines. Reduction of GSH levels by BSO produced a similar degree
of sensitization (1.6-fold) in the vector-alone control SKOV3-puro
and the MRPl-transfected cell line SKOV3-S2 (Figure 4A). In
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Figure 3 Cross-resistance profile of 2 h (open) and 96 h (shaded) of
SKOV3-puro vs SKOV3-S2 to cisplatin, JM216, AMD473, doxorubicin,
etoposide, paclitaxel and vinblastine. Resistance factor = IC50 SKOV3-S2
line/IC50SKOV3-puro line. Values are mean from 2 three experiments
Table 1 Cross-resistance profile of CORL23 vs CORL23/R (MRP positive)
CORL23 CORL23/R RF
IC50 (9M) IC50 (9M)
Doxorubicin 0.006 0.16 23.5
0.026 0.52
Etoposide 0.23 + 0.046 12.2 ± 3.3 53
Vincristine 0.0158 ± 0.001 0.093 ± 0.008 5.9
Paclitaxel 0.0019 ± 0.00015 0.0066 ± 0.00025 3.5
Cisplatin 14 0.78 0.13
12.5 2.5
JM216 3.4 0.63 0.32
3.2 1.5
AMD473 32 5 0.29
27 11
Values represent mean ± s.d. (n > 3) or n = 2 (individual values given). RF,
resistance factor (IC50 L23R/L23 lines).
Table 2 Intracellular GSH levels in the absence or presence of BSO in
SKOV3, SKOV3-puro and SKOV3-S2 cell lines
Cell line Total GSH (nmol mg-' protein) Fold reduction
(
Without BSO With BSO
SKOV3 17.8+3.2 3.6+0.6 80
SKOV3-puro 14.8±2.2 2.2±0.6 85
SKOV3-S2 21.3±5.7 2.2±0.6 90
Values indicate mean values + s.d. n 2 six experiments.
contrast, GSH depletion induced a selective potentiation of
vincristine cytotoxicity in the MRP-overexpressing SKOV3-S2
cell line (4.1-fold) but not in the SKOV3-puro line (0.9-fold)
(Figure 4B). The S2 MRP transfected subline was 7.8-fold resistant
to vincristine compared with the SKOV3-puro control.
Intracellular cisplatin accumulation
Figure 5 shows intracellular drug accumulation in the SKOV3,
SKOV3-puro and SKOV3-S2 cells immediately after 2-h expo-
sure to 10, 25 and 50 gM cisplatin. Across the range of concentra-
tions, the vector-alone control SKOV3-puro accumulated
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Figure 4 (A and B) Cytotoxicity (2 h) of (A) cisplatin or (B) vincristine in the
absence (open) or presence (shaded) of 50 gM BSO in the SKOV3, SKOV3-
puro and SKOV3-S2 cells. The symbol * represents statistical significance
(P < 0.05). Values for cisplatin are mean ± s.d. from 2 four experiments
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Figure 5 Intracellular platinum accumulation in SKOV3 (U), SKOV3-puro (A)
and SKOV3-S2 (-) immediately after a 2-h exposure to 10, 25 and 50 gM
cisplatin. Values are mean ± s.d. from three experiments
significantly higher levels of cisplatin (3.6-fold) compared with
the parental SKOV3 line. However, there were no significant
differences in drug uptake between the SKOV3-puro and the
MRP1-transfected clone SKOV3-S2.
DISCUSSION
The MRPI phenotype is characterized by resistance of cells to a
range of MDR drugs, which include the anthracyclines and epido-
phyllotoxins, but, unlike P-glycoprotein-mediated resistance, it
does not confer resistance to paclitaxel (Kavallaris, 1997).
However, like P-glycoprotein, MRPl is also related to reduced
drug accumulation as a result of its function as an efflux pump.
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Studies have shown that MRPl can act as a GS-X pump that is
capable of transporting glutathione conjugates (Ishikawa et al,
1994; Muller et al, 1994; Jedlitschky et al, 1996). In addition,
Zaman et al (1995), Schneider et al (1995) and Versantvoort et al
(1995) have demonstrated that drug transport in MRPl- but not in
P-glycoprotein-overexpressing cells can be regulated by manipu-
lating intracellular GSH levels by BSO. As there are conflicting
published data regarding the role of the MRPl/GS-X pump in
determining platinum resistance (e.g. Fujii et al, 1994; Ishikawa
et al, 1994, 1996; Muller et al, 1994; Zaman et al, 1994; De Vries
et al, 1995), the present study is aimed at determining the role of
MRP1 in platinum resistance in a panel of human ovarian carci-
noma cell lines and their variants with acquired cisplatin resistance.
Moreover, we have also transfected a MRP1 expression vector
into an intrinsically cisplatin-resistant ovarian cell line, SKOV3,
and investigated the platinum cross-resistant properties of the
CORL23/CORL23R (doxorubicin-resistant) pair of lung cancer
cell lines in which CORL23R is known to overexpress MRP1.
Our Western blot experiments have shown no overexpression of
MRPI in any of our panel of cisplatin-sensitive and -resistant
ovarian cell lines. This appears to be in broad agreement with a
study investigating MRPI expression using immunohistochem-
istry across a wide panel of human cancer cell lines; in particular,
ovarian lines tended to show relatively low expression (Izquierdo
et al, 1996). Also, no detectable levels of P-glycoprotein were
observed in any of the ovarian cell lines and in the SKOV3-puro
and SKOV3-S2 lines (data not shown). The role of another newly
described protein associated with multidrug resistance, termed the
lung resistance protein (LRP or 110-kDa human vault protein)
(Scheffer et al, 1995). was investigated in our panel of cisplatin-
sensitive and -resistant cell lines. LRP overexpression has been
found to predict a poor response to chemotherapy in acute myeloid
leukaemia and ovarian carcinoma. However, no correlation
between the expression of LRP and cisplatin sensitivity was
observed in our cell line models, as detected by immunohisto-
chemistry using the mouse monoclonal antibody LRP-56 (kindly
provided by Professor RJ Scheper, Amsterdam) (data not shown).
Transfection of MRP1 into the cell line SKOV3-S2 conferred
resistance to doxorubicin, vincristine and etoposide but not to
paclitaxel and vinblastine. These cross-resistance results are in
agreement with observations made in a MRPI-transfected HeLa
cell line (Cole et al, 1994) and the SW-1573 lung cancer cell line
(Zaman et al, 1994).
Specifically in relation to platinum drugs, our data for cisplatin
showing a lack of cross-resistance in the MRPI-transfected
SKOV3 cell line are in agreement with those reported in the HeLa
line (Cole et al, 1994). Our present work has extended the study of
MRPI and platinum drugs to include two compounds, the orally
active, more lipophilic platinum IV drug JM216, now in phase II
clinical trial, and AMD473, a sterically hindered platinum II agent
shown to possess less reactivity toward GSH than cisplatin and
about to enter a phase I clinical trial. For all three agents, there was
no evidence of MRP1 contributing to resistance in the SKOV3
ovarian model. Moreover, there was a complete lack ofcross-resis-
tance observed to these platinum drugs in the CORL23/R (23-fold
doxorubicin resistant, MRP1 positive) cell line, whereas resistance
was observed to etoposide and vincristine. These results,
combined with the lack of MRP1 expression across our panel of
ovarian cell lines of differing intrinsic sensitivity to cisplatin (and
varying levels of GSH) and in three sublines possessing acquired
cisplatin resistance, suggest that MRP1 does not play a role in
determining platinum drug sensitivity in these lines. While in
agreement with the above reports using other MRPI-transfected
lines, they differ from observations made by Ishikawa and
colleagues using cisplatin-resistant murine leukaemia cells
(Ishikawa et al, 1994, 1996). While the reasons for these differing
findings are unknown, they may relate to cell line-specific effects
(leukaemia vs ovarian carcinoma). The GS-X pump has been
shown to play a role in the efflux of platinum in one other
cisplatin-resistant human epidermoid cell line (KCP-4 cells, 25-
fold resistant) (Fujii et al, 1994). In addition, another MRPI-
related gene, the human canalicular multispecific organic anion
transporter gene (cMOAT or MRP2) has recently been shown to be
overexpressed in cisplatin-resistant human cancer cell lines with
decreased drug accumulation (four to sixfold increase in mRNA
expression) (Taniguchi et al, 1996).
As a further measure of possible importance of MRP1 in deter-
mining sensitivity to cisplatin, we have investigated the effects of
manipulating GSH levels using the gamma glutamylcysteine
synthetase inhibitor BSO, and we have measured cisplatin trans-
port in the SKOV3 MRPI-transfected line. Many studies have
reported a correlation between cisplatin resistance and increased
intracellular detoxification via elevated GSH levels (for review,
see Andrews and Howell, 1990). Our previous studies have shown
that SKOV3 cells contain 2-4-fold higher GSH levels than the
relatively cisplatin-sensitive cell lines 41M and CHI (Mistry et al,
1991). The addition of BSO to SKOV3, the vector-alone control
SKOV3-puro and the MRPI-transfected line SKOV3-S2 reduced
the levels of GSH by 80-90%. However, resistance to cisplatin
was significantly reversed (by depletion of GSH) in all cell lines
regardless of MRP1 status (by 1.6-fold). In contrast, under iden-
tical experimental conditions, depletion of GSH by BSO selec-
tively enhanced the cytotoxicity of vincristine 4.1-fold in the
MRPI-transfected line, while no change in cytotoxicity was
observed in the empty vector puromycin control line. Other studies
have reported that the sensitivity of daunorubicin, vincristine and
rhodamine 123 was enhanced in the presence of BSO in MRPl-
overexpressing cell lines (Versantvoort et al, 1995). This effect of
BSO on drug resistance was shown to be associated with an
increase in intracellular drug accumulation. However, no signifi-
cant differences in cisplatin uptake were observed between the
SKOV3-puro and the SKOV3-S2 cells. Interestingly, there was a
3.6-fold increase in platinum accumulation in the SKOV3-puro
and SKOV3-S2 lines compared with the parental SKOV3 line,
although this was not manifest as a difference in IC50 to cisplatin
(2-h IC 5 values of SKOV3 and SKOV3-puro are 31.6±8.8 and
31.0±7.6 JtM respectively). This difference in uptake could be
attributable to the method of transfection (using cationic lipids),
which may have an effect on the cell membrane of the transfected
line or reflect clonal heterogeneity with the parental line.
In summary, taking together our data using human ovarian cell
lines with intrinsic and acquired cisplatin resistance, MRPl-trans-
fected lines and a doxorubicin-resistant MRP1-overexpressing
line, there does not appear to be a significant role for MRP1 in
platinum resistance in these models.
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